Fexofenadine Induced Spontaneous Ejaculations: Rare Case with Literature Review
Tóm tắt
Second-generation antihistamines (SGAHs) are used in allergic conditions such as rhinitis, allergic asthma, hay fever, and urticaria. They are well tolerated and more efficacious than first-generation antihistamines. SGAHs include fexofenadine, belastine, cetirizine, and levocetirizine. In therapeutic doses, these drugs are safe with very few and mild side effects. Here, we report a rare side effect of fexofenadine in our patient that has not been previously reported in the literature. A 25-year-old male, known case of asthma, presented with complaints of multiple episodes of spontaneous ejaculations without any sexual stimuli. He was using fexofenadine tablets for his allergic symptoms. All physical and laboratory examinations and imaging studies were unremarkable. His complaint was attributed to fexofenadine use, as he had experienced such episodes in the past when he was using the stated drug. When the drug was stopped, within 4 days, his complaint of spontaneous ejaculation resolved, and the rechallenge test was positive. Although very safe, clinicians should be vigilant for unusual and rare side effects of commonly used medicines such as fexofenadine. Rare side effects of drugs should be reported so clinicians can recognize them and choose alternate drugs for patients.
Tài liệu tham khảo
Sanchez-Borges M, Ansotegui IJ. Second generation antihistamines: an update. Curr Opin Allergy Clin Immunol. 2019;19(4):358–64.
Huang CZ, Jiang ZH, Wang J, Luo Y, Peng H. Antihistamine effects and safety of Fexofenadine: a systematic review and meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019;20(1):72. https://doi.org/10.1186/s40360-019-0363-1.
Craun KL, Schury MP. Fexofenadine. [Updated 2020 Mar 11]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556104/.
World Health Organization (WHO). Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. Available at: https://www.who-umc.org/media/164200/who-umc-causality-assessment_new-logo.pdf.
Maintz L, Novak N. Histamine and histamine intolerance. Am J Clin Nutr. 2007;85(5):1185–96. https://doi.org/10.1093/ajcn/85.5.1185.
Lieberman P. The basics of histamine biology. Ann Allergy Asthma Immunol. 2011;106(2):S2–5. https://doi.org/10.1016/j.anai.2010.08.005.
Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, et al. International union of basic and clinical pharmacology. XCVIII. Histamine receptors. Pharmacol Rev. 2015;67(3):601–55.
Scammell TE, Jackson AC, Franks NP, Wisden W, Dauvilliers Y. Histamine: neural circuits and new medications. Sleep. 2019;42(1):zsy183. https://doi.org/10.1093/sleep/zsy183.
Alwaal A, Breyer BN, Lue TF. Normal male sexual function: emphasis on orgasm and ejaculation. Fertil Steril. 2015;104(5):1051–60.
Netto R Jr, Nucci D. Pharmacological characterization of kinin-induced relaxation of human corpus cavernosum. Br J Urol. 1998;81(3):432–6.
Cara A, Lopes-Martins RA, Antunes E, Nahoum CR, De Nucci G. The role of histamine in human penile erection. Br J Urol. 1995;75(2):220–4.
Teixeira CE, Faro R, Moreno RA, Netto NR Jr, Fregonesi A, Antunes E, et al. Nonadrenergic, noncholinergic relaxation of human isolated corpus cavernosum induced by scorpion venom. Urology. 2001;57(4):816–20.
Amitai Y. Clinical manifestations and management of scorpion envenomation. Public Health Rev. 1998;26(3):257–63.
Kim YC, Davies MG, Lee TH, Hagen PO, Carson CC III. Characterization and function of histamine receptors in corpus cavernosum. J Urol. 1995;153(2):506–10.
Ückert S, Wilken M, Stief C, Trottmann M, Kuczyk M, Becker A. Is there a significance of histamine in the control of the human male sexual response? Andrologia. 2012;44:538–42.
Abdel-Hamid IA, Elsaied MA, Mostafa T. The drug treatment of delayed ejaculation. Transl Androl Urol. 2016;5(4):576.
Jefferys A, Siassakos D, Wardle P. The management of retrograde ejaculation: a systematic review and update. Fertil Steril. 2012;97(2):306–12.
Kamischke A, Nieschlag E. Update on medical treatment of ejaculatory disorders 1. Int J Androl. 2002;25(6):333–44.
Theunissen EL, Vermeeren A, Vuurman EF, Ramaekers JG. Stimulating effects of H1-antagonists. Curr Pharm Des. 2006;12(20):2501–9.
Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: influences on male sexual behavior. Physiol Behav. 2004;83(2):291–307.
Dringenberg HC, de Souza-Silva MA, Schwarting RK, Huston JP. Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade. Naunyn Schmiedeberg's Arch Pharmacol. 1998;358(4):423–9.
Oishi R, Shishido S, Yamori M, Saeki K. Comparison of the effects of eleven histamine H 1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedeberg's Arch Pharmacol. 1994;349(2):140–4.
Matsunaga K, Sato T, Shuto H, Tsuruta Y, Suemaru K, Gomita Y, et al. Inhibition of neuronal dopamine uptake by some antiallergic drugs. Eur J Pharmacol. 1998;350(2–3):165–9.
Korotkova TM, Haas HL, Brown RE. Histamine excites GABAergic cells in the rat substantia nigra and ventral tegmental area in vitro. Neurosci Lett. 2002;320(3):133–6.
Sharif NA, Su SX, Yanni JM. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies. J Ocul Pharmacol. 1994;10(4):653–64.
Monti JM, Jantos H, Ponzoni A, Monti D. Sleep and waking during acute histamine hs agonist BP 2.94 or hs antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology. 1996;15(1):31–5.
Lepor H. Pathophysiology of benign prostatic hyperplasia in the aging male population. Rev Urol. 2005;7(Suppl 4):S3–S12.
Ventura S, Oliver V, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br J Pharmacol. 2011;163(5):891–907.
Kester RR, Mooppan UM, Gousse AE, Alver JE, Gintautas J, Gulmi FA, et al. Pharmacological characterization of isolated human prostate. J Urol. 2003;170(3):1032–8.
Normandin DE, Lodge NJ. Pharmacological characterization of the isolated canine prostate. J Urol. 1996;155(5):1758–61.
Antihistamine decongestant effects on benign prostate disease. Dr. Catalona. [cited 2020 Nov 18]. Available from: https://drcatalona.com/quest/antihistamines-and-decongestants-can-worsen-symptoms-of-benign-prostate-disease/.
Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol. 2003;5(2):72–80.
Abdel-Hamid IA, Ali OI. Spontaneous ejaculation: a focused review for the clinicians. Sex Med Rev. 2020;S2050–0521(20):30116–5. https://doi.org/10.1016/j.sxmr.2020.11.001.